Reference ranges will be provided. SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/ MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 216 7.6.4.3. 12-Lead Electrocardiogram Results Twelve-lead electrocardiogram (ECG) measurements will be recorded at the pretreatment screening visit. Each ECG will be classified as “abnormal” or “normal” and the relevance of the abnormality will be recorded as “clinically significant” or “not clinically significant.” 7.6.4.4. Physical Examination Physical examinations will be performed at the pretreatment screening visit. Abnormal findings identified will be followed until resolution or stabilization. All ongoing findings will be recorded as pretreatment AEs and will be graded by CTCAE v5.0. 7.6.4.5. Vital Signs Vital signs (body temperature [centigrade or Fahrenheit], systolic and diastolic blood pressure [BP], heart rate, and respiratory rate) and weight at each visit, plus height and weight at pretreatment screening for calculation of body mass index will be summarized over time in terms of absolute values and changes from baseline by visit and treatment group. For each parameter, a shift table comparing the baseline value to the maximum on -treatment value by treatment group will be presented. 7.6.4.6. Eastern Cooperative Group Performance Status The ECOG performance status will be measured at each visit. The definition of each ECOG grade is presented in Appendix 12.3 (Oken et al, 1982). The ECOG data will be summarized by treatment group and visit. 7.6.5.